Commentary on A Large, Open-Label, Phase 3 Safety Study of DaxibotulinumtoxinA for Injection in Glabellar Lines

Dermatol Surg. 2021 Jan 1;47(1):47. doi: 10.1097/DSS.0000000000002563.
No abstract available

Publication types

  • Comment

MeSH terms

  • Botulinum Toxins, Type A*
  • Humans
  • Neuromuscular Agents*

Substances

  • Neuromuscular Agents
  • Botulinum Toxins, Type A